Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness

Seminars in Thrombosis and Hemostasis

Volumn 26, Issue 4, 2000, Pages 421-424

  Schulman, S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Continuous infusion; Hemophilia A; Hemorrhage; Inhibitors; Recombinant factor VIIa

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; BLOOD CLOTTING FACTOR 9; FIBRIN GLUE; HEPARIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; TRANEXAMIC ACID;

BLEEDING; BOLUS INJECTION; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DRUG CLEARANCE; DRUG SAFETY; HEMOPHILIA; HUMAN; INFECTION; INFUSION PUMP; MONITORING; PRIORITY JOURNAL; REVIEW; THROMBOPHLEBITIS;

AUTOANTIBODIES; COST-BENEFIT ANALYSIS; DRUG MONITORING; FACTOR VII; HEMOPHILIA A; HUMANS; INFUSIONS, INTRAVENOUS; ISOANTIGENS; RECOMBINANT PROTEINS;

EID: 0033763660     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Successful use of recombinant factor VIIa in patient with severe haemophilia A during synovectomy
2. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa
3. Safety, efficacy and lessons from continuous-infusion with rFVIIa
4. Continuous infusion of recombinant factor VIIa in patients with haemophilia and inhibitors. Experience in The Netherlands and Belgium
5. Experiences with continuous infusion of recombinant activated factor VII
6. Adjusted dose continuous infusion of factor VIII in patients with haemophilia A
7. Feasibility of using recombinant factor VIIa in continuous infusion
8. Continuous infusion of recombinant activated factor VII: Stability in infusion pump systems
9. Coagulation factor concentrates by continuous infusion
10. Prevention of venous thromboembolism
11. The effect of tranexamic acid on local and plasma fibrinolysis during total knee arthroplasty
12. Review of pumps for continuous infusion of coagulation factor concentrates: What are the options?